Malaria Vaccine, Reagents for malaria research

Sanaria Inc. is at the forefront of malaria vaccine development, focusing on innovative vaccines that utilize live attenuated sporozoites from the Plasmodium falciparum parasite. Their flagship product, the PfSPZ Vaccine, has demonstrated significant efficacy in clinical trials across various regions, including the United States, Germany, and several African countries. This vaccine aims to provide high-level, long-lasting protection against malaria, particularly for vulnerable populations such as pregnant women. Sanaria's research emphasizes not only individual protection but also community-wide malaria transmission reduction, with the ultimate goal of eradicating malaria in specific geographic areas.

In addition to their vaccine development efforts, Sanaria has established a comprehensive suite of products and services to support malaria research. This includes the production of aseptic, purified sporozoites and infected mosquitoes for controlled human malaria infection trials, as well as various assay services to measure immune responses. Sanaria is also collaborating with the National Institutes of Health to develop human monoclonal antibodies that offer rapid protection against malaria, providing an alternative for individuals who may not be suitable candidates for vaccination. Through these initiatives, Sanaria aims to advance the understanding of malaria pathology and immunobiology while contributing to the global fight against this deadly disease.

United States

Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.

Sanaria Inc.

Company Details